Harmony Biosciences Holdings, Inc. HRMY Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $589.4M+20.5% | $752.5M+66.1% | $647M+67.0% | $546.05M+72.1% | $489M+46.9% | ||
| $51.52M+187% | $22.84M+61.0% | $25.58M+10.7% | $19.22M-35.1% | $17.96M-54.4% | ||
| $398.64M+12.7% | $396.39M+21.1% | $382.63M+20.1% | $363.49M+19.5% | $353.66M+24.1% | ||
| $5.28M-17.3% | $5.36M-25.6% | $6.88M-0.5% | $6.1M+8.1% | $6.38M+9.0% | ||
| $16.8M+2.0% | $16.01M+16.8% | $23.31M+45.2% | $18.36M+13.9% | $16.47M+27.7% | ||
| $778.82M+21.2% | $907.01M+56.6% | $838.8M+60.6% | $691.35M+50.8% | $642.69M+34.0% | ||
| $83.46M-22.2% | $89.42M-21.1% | $95.38M-20.0% | $101.34M-19.0% | $107.3M-18.2% | ||
| $26.43M+345% | $18.37M+148% | $9.69M+55.1% | $5.47M-15.5% | $5.94M-14.8% | ||
| $229.56M+122% | $107.13M-1.6% | $105.83M+12.3% | $107.01M+22.7% | $103.25M+27.1% | ||
| $493.01M+19.4% | $364.62M-13.2% | $369.42M-8.9% | $416.65M+4.2% | $412.84M+12.3% | ||
| $1.27B+20.5% | $1.27B+27.3% | $1.21B+30.2% | $1.11B+29.1% | $1.06B+24.6% | ||
| $28.6M+63.8% | $17.69M+28.7% | $26.34M+150% | $28.3M+24.8% | $17.46M+15.3% | ||
| $6.73M-11.3% | $18.44M-1.8% | $14.94M+5.0% | $11.74M+21.7% | $7.58M+3.6% | ||
| $20M+14.3% | $20M+23.1% | $20M+33.3% | $18.75M+25.0% | $17.5M+16.7% | ||
| $1.27M+10.4% | $1.07M-18.6% | $825K-46.1% | $846K-52.6% | $1.15M-36.0% | ||
| $217.34M+24.1% | $252.13M+44.0% | $223.4M+38.5% | $180.14M+22.9% | $175.12M+13.5% | ||
| $138.81M-12.2% | $143.66M-11.9% | $148.51M-11.5% | $153.35M-10.5% | $158.18M-9.6% | ||
| $5.8M+225% | $5.59M+161% | $1.23M-48.7% | $1.28M-51.6% | $1.78M-41.9% | ||
| $5.32M+211% | $5.62M+189% | $1.19M-46.2% | $1.45M-19.4% | $1.71M-27.0% | ||
| $144.14M-9.9% | $149.28M-9.5% | $149.69M-12.0% | $154.79M-10.6% | $159.89M-9.8% | ||
| $361.48M+7.9% | $401.41M+18.0% | $373.1M+12.6% | $334.93M+4.7% | $335.01M+1.0% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $717.37M+6.7% | $708.97M+7.9% | $696.35M+8.2% | $685.29M+8.4% | $672.5M+8.4% | ||
| $193.39M+305% | $160.9M+7,161% | $138.42M+393% | $87.55M+194% | $47.78M+146% | ||
| -$413K-269% | $346K+424% | $357K-28.5% | $239K+202% | $245K+243% | ||
| $910.35M+26.3% | $870.22M+32.0% | $835.12M+39.9% | $773.08M+43.5% | $720.53M+39.8% | ||
| $1.27B+20.5% | $1.27B+27.3% | $1.21B+30.2% | $1.11B+29.1% | $1.06B+24.6% | ||
| $7.6M+9.8% | $13.52M+66.4% | $35.38M+375% | $8.64M+32.7% | $6.92M-20.4% | ||
| $26.43M+345% | $18.37M+148% | $9.69M+55.1% | $5.47M-15.5% | $5.94M-14.8% | ||
| $153.56M-21.1% | $149.7M-21.4% | $157.08M-15.1% | $201.19M+11.7% | $194.71M+31.9% | ||
| $83.46M-22.2% | $89.42M-21.1% | $95.38M-20.0% | $101.34M-19.0% | $107.3M-18.2% | ||
| $229.56M+122% | $107.13M-1.6% | $105.83M+12.3% | $107.01M+22.7% | $103.25M+27.1% | ||
| $26.43M+345% | $18.37M+148% | $9.69M+55.1% | $5.47M-15.5% | $5.94M-14.8% | ||
| $51.52M+187% | $22.84M+61.0% | $25.58M+10.7% | $19.22M-35.1% | $17.96M-54.4% | ||
| $26.43M+345% | $18.37M+148% | $9.69M+55.1% | $5.47M-15.5% | $5.94M-14.8% | ||
| $6.73M-11.3% | $18.44M-1.8% | $14.94M+5.0% | $11.74M— | $7.58M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $6.73M-11.3% | $18.44M-1.8% | $14.94M+5.0% | $11.74M— | $7.58M— | ||
| $11.91M-40.1% | $4.96M-12.6% | $825K-93.0% | $3.06M-59.9% | $19.88M-20.8% | ||
| $164.61M-7.2% | $169.25M-6.7% | $169.73M-8.4% | $173.37M-8.3% | $177.46M-8.1% | ||
| $717.37M+6.7% | $708.97M+7.9% | $696.35M+8.2% | $685.29M+8.4% | $672.5M+8.4% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $16.8M+2.0% | $16.01M+16.8% | $23.31M+45.2% | $18.36M+13.9% | $16.47M+27.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Harmony Biosciences Holdings, Inc. cover its short-term obligations?
- Its current ratio is 3.58 — current assets exceed current liabilities.
- Where does Harmony Biosciences Holdings, Inc.'s balance sheet data come from?
- Every line is extracted from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.